Globe News Wire
28 May 2026, 05:30 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/28/3302504/0/fr/de-nouvelles-donn%c3%a9es-late-breaking-renforcent-l-impact-d-iqirvo-sur-l-alp-la-fatigue-et-le-prurit-dans-la-cbp.html
Read source
Search tags
Story key points
4 claims · impact-rated
Phase III ELATIVE post hoc analysis shows IQIRVO significantly reduced fatigue in 67% of patients compared to 31% for placebo (p=0.020). — Addressing a major unmet medical need (fatigue) in CBP enhances the drug's competitive positioning and market penetration potential.
+0.60US real-world data from HealthVerity demonstrates 59% of second-line naive patients achieved ALP normalization with IQIRVO. — Real-world evidence of ALP normalization supports the drug's clinical utility and long-term prognosis claims, likely driving higher prescription rates.
+0.50Interim 3-month results from the Phase IV ELFINITY study showed biological response in 55% of patients and improvements in pruritus. — Positive Phase IV data reinforces the safety and efficacy profile in a broader clinical setting, reducing the risk of post-launch attrition.
+0.40IQIRVO maintained a favorable safety profile across studies with no reported serious or severe treatment-related adverse events. — The absence of severe side effects removes a primary barrier to adoption and reduces the risk of regulatory warnings or limited labeling.
+0.30Ticker attribution
Model heads
The company announced positive late-breaking results from Phase III and real-world studies showing IQIRVO's efficacy in reducing ALP and improving fatigue/pruritus in PBC patients.
No ticker relationship head found.
Impact vectors
7 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
